, and the 36-month beta value for VBIV is at 1.94.
The public float for VBIV is 204.57M, and currently, shorts hold a 6.76% of that float. The average trading volume for VBIV on March 16, 2023 was 926.15K shares.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
VBIV) stock’s latest price update
VBI Vaccines Inc. (NASDAQ: VBIV)’s stock price has decreased by -9.04 compared to its previous closing price of 0.37. However, the company has experienced a -13.68% decline in its stock price over the last five trading sessions.
VBIV’s Market Performance
VBIV’s stock has fallen by -13.68% in the past week, with a monthly drop of -45.04% and a quarterly drop of -34.84%. The volatility ratio for the week is 12.89% while the volatility levels for the last 30 days are 9.95% for VBI Vaccines Inc. The simple moving average for the last 20 days is -27.42% for VBIV stock, with a simple moving average of -52.57% for the last 200 days.
Analysts’ Opinion of VBIV
Many brokerage firms have already submitted their reports for VBIV stocks, with Raymond James repeating the rating for VBIV by listing it as a “Outperform.” The predicted price for VBIV in the upcoming period, according to Raymond James is $2 based on the research report published on November 11th of the previous year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see VBIV reach a price target of $6, previously predicting the price at $7. The rating they have provided for VBIV stocks is “Buy” according to the report published on December 29th, 2021.
Jefferies gave a rating of “Buy” to VBIV, setting the target price at $7 in the report published on February 25th of the previous year.
VBIV Trading at -35.28% from the 50-Day Moving Average
After a stumble in the market that brought VBIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.15% of loss for the given period.
Volatility was left at 9.95%, however, over the last 30 days, the volatility rate increased by 12.89%, as shares sank -41.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.11% lower at present.
During the last 5 trading sessions, VBIV fell by -13.68%, which changed the moving average for the period of 200-days by -61.48% in comparison to the 20-day moving average, which settled at $0.4455. In addition, VBI Vaccines Inc. saw -15.11% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VBIV
Equity return is now at value -95.90, with -59.30 for asset returns.
Conclusion
In conclusion, VBI Vaccines Inc. (VBIV) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
